AI-integrated urine-based biopsy offers life-changing technology
PanGIA Biotech, a pioneer in liquid biopsy technology from the United States, has announced its first international partnership in India, collaborating with Canary Oncoceutics (Canary Oncoceutics, Inc., Phoenix, AZ, and Canary Oncoceutics India Pvt Ltd, Tamil Nadu) https://cancerindia.org.in/.
This collaboration introduces the PanGIA® Prostate Assay, the world’s first AI-integrated urine-based liquid biopsy for prostate cancer detection, marking its commercial debut in India https://www.bseindia.com/.
“Launching our patented PanGIA Prostate Assay in India marks an important milestone for our company and healthcare innovation,” said Holly Magliochetti, CEO of PanGIA Biotech https://www.nseindia.com/.
“Partnering with Canary Oncoceutics enables us to bring life-changing technology to a population in need, reinforcing our commitment to saving lives, changing lives, and giving back by advancing healthcare equity.
“This non-invasive, accurate, and culturally sensitive diagnostic tool is poised to enhance early prostate cancer detection and improve patient outcomes,” Magliochetti said in a release from Florita on 12 Dec http://main.mohfw.gov.in.
“With this partnership agreement, we can offer a unique test to the medical community in India,” said Dr. Harry Lander, CEO and co-founder of Canary Oncoceutics, Inc. “Our extensive presence in India allows us to rapidly deploy the PanGIA Prostate Assay.”
PanGIA Biotech is actively advancing its R&D pipeline, targeting 10 additional cancers including lung, pancreatic, ovarian, and breast. The company is also focused on validating its multi-cancer assay and expanding its global impact through continued innovation, offering long-term growth potential for partners http://who.int.
PanGIA cited a report from the World Health Organization’s Global Cancer Observatory (GLOBOCAN) which estimates that prostate cancer is a significant health concern for men in India. Hebert, et al reported that about 85% of prostate cancers in India were detected at late (III and IV) stage; in contrast to the US where 15% of prostate cancer is diagnosed at late stage. These figures highlight the importance of early detection for improving outcomes and reducing mortality rates https://sbi.com.in/.
“The only way to mitigate the harm caused by rising case numbers is to urgently set up systems for earlier diagnosis in Low- and Middle- Income Countries,” according to the Lancet Commission on Prostate Cancer (2024). PanGIA Biotech develops AI-integrated liquid biopsy technology designed for global scalability. Fiinews.com
